Senators Push Park Doctrine Prosecution For Spiked Supplement ‘Criminal Endeavors’

Key industry allies say they are “deeply concerned” about “blatant criminal activity” in products marketed as supplements but containing anabolic steroids or other drugs. “Bring a few of these actions and you scare people into the idea that … you could actually go to jail,” says attorney Frederick Stearns.

The dietary supplement industry’s Senate champions urge Park Doctrine prosecutions against marketers of spiked products, saying convictions leading to jail time would “incapacitate current criminal endeavors and deter new criminality.”

Sens. Orrin Hatch, R-Utah, and Martin Heinrich, D-NM, on May 19 sent a letter congratulating Attorney General Loretta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More Telework, More Staff, US FDA’s Tidmarsh Plans To Alleviate Workforce Challenges

 

The new CDER director focused on plans to improve morale during an Aug. 8 townhall, but staff comments indicate that may be a challenge.

US Pricing Reform: New Products Offer ‘On Ramp’ To Implementation, Lilly’s Ricks Says

 
• By 

Eli Lilly's CEO argued that pricing reforms aimed at existing drugs would be “hard to sustain or justify,” while other companies suggested a growing interest in direct-to-consumer sales programs.

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

EU Must Up Competitiveness To Counter US Tariffs And Pricing Woes For SMEs

 

Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.

More from North America